Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allogeneic bone marrow-derived mesenchymal stromal cell secretome
- Development stage
- Phase 2
- Lead developer
- University of Illinois Chicago
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Ophthalmic, Topical
01
Overview
This is an investigational cell-free biologic therapy consisting of the secretome (a collection of secreted factors) derived from allogeneic human bone marrow mesenchymal stromal cells (MSCs). Developed by the University of Illinois at Chicago, it is formulated as topical eye drops for treating persistent corneal epithelial defects (PCED) and other non-resolving corneal epithelial diseases. The secretome contains a variety of cytokines, growth factors, and extracellular vesicles (exosomes) that mediate wound healing by promoting the migration and proliferation of corneal epithelial cells while exerting immunomodulatory and anti-inflammatory effects on the ocular surface. This approach aims to provide the regenerative benefits of MSC therapy without the risks and logistical challenges associated with live cell transplantation.
- Other names
- Topical Mesenchymal Stromal Cell SecretomeMSC secretome eye dropsAllogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome
Beyond the preview
Go deeper on Allogeneic bone marrow-derived mesenchymal stromal cell secretome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allogeneic bone marrow-derived mesenchymal stromal cell secretome.